Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBITDA Margin (2016 - 2025)

Vanda Pharmaceuticals' EBITDA Margin history spans 16 years, with the latest figure at 70.0% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 5108.0% to 70.0% in Q4 2025 year-over-year; TTM through Dec 2025 was 69.44%, a 4942.0% decrease, with the full-year FY2025 number at 69.44%, down 4942.0% from a year prior.
  • EBITDA Margin hit 70.0% in Q4 2025 for Vanda Pharmaceuticals, down from 55.07% in the prior quarter.
  • Over the last five years, EBITDA Margin for VNDA hit a ceiling of 18.72% in Q2 2021 and a floor of 81.53% in Q1 2025.
  • Historically, EBITDA Margin has averaged 15.8% across 5 years, with a median of 13.57% in 2022.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 1666bps in 2021 and later crashed -6250bps in 2025.
  • Tracing VNDA's EBITDA Margin over 5 years: stood at 13.19% in 2021, then dropped by -19bps to 10.72% in 2022, then tumbled by -242bps to 15.22% in 2023, then decreased by -24bps to 18.91% in 2024, then crashed by -270bps to 70.0% in 2025.
  • Business Quant data shows EBITDA Margin for VNDA at 70.0% in Q4 2025, 55.07% in Q3 2025, and 72.71% in Q2 2025.